↓ Skip to main content

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.

Overview of attention for article published in Clinical Cancer Research, April 2023
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

twitter
230 X users
reddit
2 Redditors

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
12 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.
Published in
Clinical Cancer Research, April 2023
DOI 10.1158/1078-0432.ccr-22-1912
Pubmed ID
Authors

Juan Bautista Blaquier, Sandra Ortiz-Cuaran, Biagio Ricciuti, Laura Mezquita, Andrés Felipe Cardona, Gonzalo Recondo

X Demographics

X Demographics

The data shown below were collected from the profiles of 230 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 50%
Unspecified 1 8%
Student > Ph. D. Student 1 8%
Professor 1 8%
Unknown 3 25%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 25%
Agricultural and Biological Sciences 2 17%
Medicine and Dentistry 2 17%
Unspecified 1 8%
Engineering 1 8%
Other 0 0%
Unknown 3 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 180. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 February 2024.
All research outputs
#234,369
of 26,277,952 outputs
Outputs from Clinical Cancer Research
#101
of 13,413 outputs
Outputs of similar age
#5,665
of 420,333 outputs
Outputs of similar age from Clinical Cancer Research
#4
of 130 outputs
Altmetric has tracked 26,277,952 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,413 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 420,333 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 130 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.